AMGN241213P260000
- 0.03
- -0.03-50.00%
Amgen Newsroom
Dow's 112-Point Fall Led By Losses In NVIDIA Corp., Amgen Shares
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Unpacking the Latest Options Trading Trends in Amgen
Why Amgen Inc. (AMGN) Is the Best Safe Stock to Buy According to Analysts?
Amgen To Go Ex-Dividend On February 14th, 2025 With 2.38 USD Dividend Per Share
December 11th (Eastern Time) - $Amgen(AMGN.US)$ is trading ex-dividend on February 14th, 2025.Shareholders of record on February 14th, 2025 will receive 2.38 USD dividend per share on March 7th, 2025.
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Oppenheimer Remains a Buy on Amgen (AMGN)
BofA Restarts Coverage of 11 Large-cap Biopharmas
Amgen Increases Quarterly Dividend to $2.38, Payable March 7 to Shareholders of Record Feb. 14
Amgen Raises Qtr Dividend to $2.38 Vs. $2.25 >AMGN
Express News | Amgen Announces 2025 First Quarter Dividend
Unusual Options Activity: AI, MSTR and Others Attract Market Bets, AI V/OI Ratio Reaches 249.3
EST Dec 10th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Express News | Amgen Shares Down 1.7% After BofA Global Research Reinstates Coverage With Underperform Rating
Demystifying Amgen: Insights From 13 Analyst Reviews
B of A Securities Reinstates Underperform on Amgen, Announces $256 Price Target
Amgen Analyst Ratings
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
Amgen Announced Blincyto Added To Chemotherapy Significantly Improves Survival In Newly Diagnosed Pediatric Patients With B-cell Precursor Acute Lymphoblastic Leukemia At ASH; Said Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival...